Abstract
The article discusses the financial instruments of diagnostics strategies of pharmaceutical companies. The purpose of such tools is to assess the strengths and weaknesses of public health services in low- and middle-income countries. The aim of the work is to help government officials and their development partners make an informed choice as to which tool, if any, can meet their specific needs. The available eight options are described and the advantages and disadvantages of specific tools are highlighted in the context of a brief discussion of the problems and possibilities of measurement and diagnostics in general.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
